In this video as part of The Motley Fool's "Ask a Fool" series, Fool health-care analyst David Williamson takes a question from a Fool reader, who asks, "Gilead Sciences (NASDAQ:GILD) seems to be on a down trend. Is there any specific reason, or should I just hold firm?"
David takes a look at Gilead's downward trend year to date but cautions that this 3% pullback since the beginning of 2014 is much better understood in the context of the stock's meteoric rise over the past 12 months. He then discusses for investors the company's hepatitis C drug Sofosbuvir, sold under the name Sovaldi, and how much of the investing thesis is based around the success of this drug. He notes that while the drug is destined to be a blockbuster with an incredible cure rate, it has its risks that investors need to be aware of. Finally, David looks at Gilead's pipeline, and the future of the company.
David Williamson has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
2017 Was a Year to Forget for Gilead Sciences, Inc., but This Year Could Be Better
In the short term, the biotech's success is still tied to its HIV and HCV franchises, but keep an eye on the pipeline.
5 Ways Gilead Sciences Plans to Return to Growth
Gilead's CEO reveals the biotech's game plan at the J.P. Morgan Healthcare Conference.
3 Top Healthcare Stocks to Buy in January
These prominent drug developers look to be enticing buys this month.